# Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

> **NCT04744116** · EARLY_PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Steroid Refractory Graft Versus Host Disease

## Interventions

- **OTHER:** Cellular Therapy
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04744116
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-17
- **Primary completion:** 2032-03-31
- **Final completion:** 2032-03-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04744116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04744116, "Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04744116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*